Dr Reddy Laboratories Ltd

All five India-focused funds have their highest individual sectoral exposure to financials. As reported in the news, 2015 has been a year of global economic stress.

Market Realist analysts recently conducted a Q&A with experts from VanEck on the generic pharmaceutical industry, a space that has attracted investor interest due to upside potential from brand name drugs coming off patent, cost saving pressure in the healthcare industry, and increased worldwide demand for prescription drugs (for more on these topics, please see […]

Enbrel, Neulasta, and Epogen are among Amgen’s (AMGN) major revenue-generating drugs, each with annual sales in excess of $1 billion. Enbrel and Neulasta together accounted for ~46% of Amgen’s 2016 revenues.

Banks saw a rise in term deposit accounts since the demonetization. As a result, commercial banks sharply reduced their deposit rates.

Equities gain Indian equities rose on October 4, 2016, the day of the RBI’s (Rerserve Bank of India) latest monetary policy announcement. The central bank’s cut of its repo rate had a positive effect on equities, with bonds rising initially along with the Indian rupee. Banking and telecom stocks were among major gainers during the […]

Indian equities fell on August 9, the day of the monetary policy announcement. Benchmark equity indices like the S&P BSE Sensex and the Nifty 50 fell 0.4%.

Kuvan, with the active ingredient sapropterin dihydrochloride, is effective in reducing blood phenylalanine levels in PKU (or phenylketonuria) patients.

Indian stocks had a strong run in the last half of 2014 through early 2015, but the ride since then hasn’t been smooth. The INDA is up only 2.6% in the one year ended June 2015.